Omnio
Recombinant plasminogen therapy for hard-to-heal chronic wounds
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Omnio is a Umeå, Sweden biotech developing a recombinant plasminogen-based drug candidate to restart healing in chronic wounds such as diabetic foot ulcers. The company is advancing manufacturing toward GMP readiness and clinical development for wounds that fail conventional care. Based at Uminova Science Park.
- Website
- omnio.se
- Stage
- seed
- Location
- Umeå, Sweden
- Contact
- info@omnio.se
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Omnio Rec-PLG — Recombinant plasminogen candidate for chronic wound healing